Last 47.50 GBp
Change Today -2.25 / -4.52%
Volume 287.9K
VER On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
OTC US
As of 11:35 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

Open
47.00 GBp
Previous Close
49.75 GBp
Day High
47.50 GBp
Day Low
45.25 GBp
52 Week High
12/5/14 - 53.00 GBp
52 Week Low
06/3/14 - 28.75 GBp
Market Cap
210.1M
Average Volume 10 Days
372.2K
EPS TTM
-0.03 GBp
Shares Outstanding
442.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; and Tris Pharma Inc. Vernalis plc is headquartered in Winnersh, the United Kingdom.

89 Employees
Last Reported Date: 03/31/14

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 610.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 417.0K GBP
Compensation as of Fiscal Year 2013.

vernalis plc (VER) Key Developments

Vernalis plc Changes Financial Year End from December 31 to June 30

Vernalis plc announced a change to its accounting reference date and financial year end from 31 December to 30 June. The company's board has taken the decision to change the accounting reference date and financial year-end from 31 December to 30 June to align the external reporting period with the seasonality of the US cough cold market which will become a major component of the Company's future commercial business.

Vernalis PLC Announces CTI BioPharma Corp. Replaces the Chroma Therapeutics as Worldwide Licensee of Tosedostat

Vernalis plc announced that CTI BioPharma Corp., replaces the Chroma Therapeutics (Chroma) as worldwide licensee of tosedostat. CTI previously held rights to tosedostat in the Americas under a Licence Agreement with Chroma. Chroma no longer retains any ongoing rights or financial interest in tosedostat. The financial terms of the Licence Agreement with CTI, which are the same as those in the prior agreement with Chroma, provide for Vernalis to receive tiered single digit percentage royalties. Tosedostat is in Phase II studies to treat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Vernalis plc Opens US Office in Berwyn, Pennsylvania; Appoints Pascal Borderies, as SVP Medical Affairs

Vernalis plc announced it has opened its US office in Berwyn, Pennsylvania. The company has strengthened its US Executive team with the appointment of Dr. Pascal Borderies, as SVP Medical Affairs. A physician by training, Pascal joins Vernalis from Aptalis Pharma Inc., bringing with him a wealth of clinical and commercial experience, in both prescription (Schering-Plough) and OTC (Novartis Consumer Health) markets. Whilst at Novartis, Pascal was Director - Global Head Cough-Cold Respiratory, Pain and New Growth Opportunities. Pascal's appointment further strengthens US Executive Management team and he will be working closely with Tom Parker, SVP Commercial Operations. The Berwyn office will be the central location for US operations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 47.50 GBp -2.25

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,401 +31.00
Endo International PLC $73.00 USD +1.69
Grifols SA €33.21 EUR +0.59
Impax Laboratories Inc $31.32 USD +0.54
STADA Arzneimittel AG €25.80 EUR -0.222
View Industry Companies
 

Industry Analysis

VER

Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit www.vernalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.